<- Go Home
Verici Dx plc
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Market Cap
GBP 20.5M
Volume
292.1K
Cash and Equivalents
GBP 2.6M
EBITDA
-GBP 7.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 1.0M
Profit Margin
100.00%
52 Week High
GBP 0.17
52 Week Low
GBP 0.07
Dividend
N/A
Price / Book Value
4.04
Price / Earnings
-1.65
Price / Tangible Book Value
9.80
Enterprise Value
GBP 18.4M
Enterprise Value / EBITDA
-2.42
Operating Income
-GBP 8.4M
Return on Equity
115.94%
Return on Assets
-48.36
Cash and Short Term Investments
GBP 2.6M
Debt
GBP 540.0K
Equity
GBP 3.6M
Revenue
GBP 1.0M
Unlevered FCF
-GBP 3.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium